AVXL vs PVLA
AVXL: A clinical-stage biopharma company developing precision medicine treatments for Alzheimer's, Parkinson's, and rare CNS diseases by targeting the sigma-1 receptor. PVLA: A clinical-stage biopharmaceutical company developing proprietary therapeutics for rare skin diseases and vascular malformations following the merger of Pieris Pharmaceuticals and Legacy Palvella.
Side-by-side fundamentals
| Metric | AVXL | PVLA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $2.50 | $141.77 | |
| Market cap as of 2026-08-03 | $232M | $2.0B | |
| Net margin as of 2026-08-03 | n/a | -39.7% | |
| Operating margin as of 2026-08-03 | n/a | -47.8% | |
| ROE as of 2026-08-03 | -38.8% | -56.9% | AVXL higher |
| ROA as of 2026-08-03 | -35.0% | -42.5% | AVXL higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.09 | AVXL lower |
| Revenue growth (YoY) as of 2026-08-03 | n/a | -97.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +13.4% | |
| Beta as of 2026-08-03 | 1.15 | -0.20 | |
| 1-year return as of 2026-07-27 close | -79.4% | +267.1% | PVLA higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.